[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Ayadi L, Zribi J, Mziou TJ, Ellouz S, Khabir A, Bahri I, Turki H, Sellami-Boudawara T: [Scalp metastasis from small cell carcinoma of the rectum: an unusual case]. Tunis Med; 2009 May;87(5):354-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Scalp metastasis from small cell carcinoma of the rectum: an unusual case].
  • BACKGROUND: Cutaneous metastasis of rectal carcinoma is a rare event.
  • It occurs in 4% of all patients with rectal cancer.
  • Skin metastasis of rectal cancer are usually detected near the initial tumor, especially in the periumbilical region; but they rarely occur in the scalp.
  • AIM: To report a new case of scalp metastases from rectal tumor.
  • CASE REPORT: Our patient was a 63-year old male with a history of small cell carcinoma of the rectum who subsequently developed a single nodule of the scalp of 4cm.
  • Histopathological analysis revealed a small cell carcinoma infiltrating the dermis and subcutaneous tissue.
  • The patient underwent palliative chemotherapy but his disease continued to progress.
  • CONCLUSION: In contrast to the prior cases of scalp metastases reported in the literature, ours is the first documentation of such an occurrence from rectal small cell carcinoma.
  • The early diagnosis of skin metastases in these patients is very important because it can alter treatment.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Rectal Neoplasms / pathology. Scalp. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927770.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


2. Hashimoto Y, Kimura G, Tsuboi N, Akimoto M: [A case of prostatic small cell carcinoma]. Hinyokika Kiyo; 2000 Jun;46(6):425-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostatic small cell carcinoma].
  • Digital rectal examination showed an enlarged, irregular prostate with stony hardness.
  • Abdominal computed tomography showed enlarged common iliac and paraaortic lymph nodes, and multiple liver metastases.
  • Histological and immunohistochemical examinations indicated small cell carcinoma and adenocarcinoma of the prostate.
  • Chemotherapy could not be performed due to acute hepatic failure.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Small Cell / pathology. Neoplasms, Multiple Primary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10934615.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 5
  •  go-up   go-down


3. Ihtiyar E, Algin C, Isiksoy S, Ates E: Small cell carcinoma of rectum: a case report. World J Gastroenterol; 2005 May 28;11(20):3156-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of rectum: a case report.
  • We present a case of a 40-year-old woman with small-cell carcinoma (SCC) of the rectum.
  • After the diagnosis of SCC, she received intravenous chemotherapy with standard doses of siklofosfamid, adriamycin, and vepesid.
  • [MeSH-major] Carcinoma, Small Cell. Rectal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918209.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305859
  •  go-up   go-down


Advertisement
4. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA: Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum; 2008 Nov;51(11):1641-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
  • PURPOSE: The response of rectal cancers to neoadjuvant chemoradiotherapy is variable.
  • Tumor hypoxia reduces the effectiveness of both radiation therapy and chemotherapy and is a well-known risk factor for tumor radioresistence.
  • We hypothesized that imaging with the novel hypoxia-detecting agent, (60)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) ((60)Cu-ATSM), previously validated in cervical and lung cancers, would predict the response of rectal cancers to neoadjuvant chemoradiotherapy and prognosis.
  • METHODS: Patients with locally invasive (T2-4) primary or node-positive rectal cancer located <12 cm from the anal verge were recruited for this pilot study.
  • Eleven patients also underwent clinical positron emission tomography with (18)F-fluorodeoxyglucose at the discretion of the treating clinician.
  • The primary tumor was imaged by positron emission tomography with (60)Cu-ATSM, and accumulation of the tracer was measured semiquantitatively by determining the tumor-to-muscle activity ratio.
  • Neoadjuvant chemoradiotherapy was then administered (within 2 weeks of (60)Cu-ATSM-positron emission tomography) and consisted of 45 Gy given in 25 fractions to the pelvis with continuous intravenous infusion of 5-fluorouracil (225 mg/m(2)/day).
  • CONCLUSIONS: The results of this small pilot study suggest that (60)Cu-ATSM-PET may be predictive of survival and, possibly, tumor response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Organometallic Compounds. Positron-Emission Tomography. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Thiosemicarbazones
  • [MeSH-minor] Adult. Aged. Cell Hypoxia. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects. Predictive Value of Tests. Prognosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682881.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R24 CA086307
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
  • [Other-IDs] NLM/ NIHMS802312; NLM/ PMC4962601
  •  go-up   go-down


5. Chapet O, Corcelle-Requin A, Padovani L, Bizollon MH, Mérieux C, Trillet-Lenoir V, Gérard JP: [Anorectal neuroendocrine carcinoma and small cell carcinoma. Report of two cases]. Rev Med Interne; 2001 Nov;22(11):1109-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anorectal neuroendocrine carcinoma and small cell carcinoma. Report of two cases].
  • [Transliterated title] Carcinome neuroendocrine à petites cellules de la région anorectale: à propos de deux cas.
  • INTRODUCTION: Anorectal neuroendocrine small cell carcinomas are rare and frequently difficult to treat.
  • Histology displayed neuron-specific enolase and chromogranin A immunoreactive small cell tumors.
  • Tumors were poorly reactive to chemotherapy and irradiation, less than in usual epidermoid anal canal cancer.
  • CONCLUSION: Anorectal neuroendocrine small cell carcinomas are rare but need to be individualized from epidermoid anal canal tumors owing to their poor prognosis with a frequent occurrence of hepatic and pulmonary metastasis.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11817122.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Nielsen SS, He Y, Ayanian JZ, Gomez SL, Kahn KL, West DW, Keating NL: Quality of cancer care among foreign-born and US-born patients with lung or colorectal cancer. Cancer; 2010 Dec 1;116(23):5497-506
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Logistic regression was used to assess the association between nativity and patient-reported quality of care and receipt of recommended treatments (adjuvant chemotherapy for stage III colon cancer, adjuvant chemotherapy and radiotherapy for stage II/III rectal cancer, and curative surgery for stage I/II nonsmall cell lung cancer).
  • Rates of recommended therapies ranged from 64% to 85%; foreign-born patients were less likely to receive chemotherapy and radiotherapy for stage II/III rectal cancer (AOR, 0.35; 95% CI, 0.12-0.99).
  • Rates of other treatments did not differ significantly by nativity.
  • CONCLUSIONS: Foreign-born cancer patients reported lower quality of care and were less likely to receive some cancer therapies than patients born in the Unites States.
  • Better coordination of care and communication regarding cancer treatments and expanded use of interpreters may lessen these disparities.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] Stat Methods Med Res. 2010 Dec;19(6):653-70 [19654173.001]
  • [Cites] J Clin Oncol. 2010 Sep 20;28(27):4154-61 [20713876.001]
  • [Cites] J Gen Intern Med. 2001 Jul;16(7):468-74 [11520385.001]
  • [Cites] Am J Epidemiol. 2001 Sep 15;154(6):582-7 [11549564.001]
  • [Cites] Int J Epidemiol. 2001 Oct;30(5):976-82 [11689507.001]
  • [Cites] Med Care. 2002 Jan;40(1):52-9 [11748426.001]
  • [Cites] Int J Epidemiol. 2002 Apr;31(2):511-3; author reply 513 [11980831.001]
  • [Cites] Am J Public Health. 2002 Nov;92(11):1757-9 [12406802.001]
  • [Cites] Chest. 2002 Dec;122(6):1938-43 [12475830.001]
  • [Cites] Am J Manag Care. 2003 Jul;9(7):502-9 [12866629.001]
  • [Cites] Ethn Dis. 2004 Winter;14(1):134-40 [15002933.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):243-53 [15090719.001]
  • [Cites] Ethn Dis. 2004 Spring;14(2):292-5 [15132217.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2992-6 [15284250.001]
  • [Cites] Am J Public Health. 1999 Aug;89(8):1248-52 [10432917.001]
  • [Cites] J Clin Epidemiol. 2005 Apr;58(4):364-9 [15862722.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4679-86 [15851764.001]
  • [Cites] Cancer Causes Control. 2005 Aug;16(6):713-23 [16049810.001]
  • [Cites] J Gen Intern Med. 2005 Jul;20(7):604-11 [16050854.001]
  • [Cites] Cancer Detect Prev. 2005;29(4):361-8 [16081223.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6576-86 [16116149.001]
  • [Cites] J Clin Epidemiol. 2005 Dec;58(12):1316-9 [16291477.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):184-92 [16721803.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):221-6 [16839213.001]
  • [Cites] Health Serv Res. 2007 Apr;42(2):727-54 [17362215.001]
  • [Cites] J Womens Health (Larchmt). 2007 Dec;16(10):1447-57 [18062760.001]
  • [Cites] J Cancer Educ. 2008 Jan-Mar;23(1):18-25 [18444042.001]
  • [Cites] Med Care. 2008 Sep;46(9):963-8 [18725851.001]
  • [Cites] Med Care Res Rev. 2009 Aug;66(4):355-408 [19179539.001]
  • [Cites] J Gen Intern Med. 2009 Aug;24(8):963-70 [19472016.001]
  • [Cites] BMC Public Health. 2009;9:246 [19615070.001]
  • [Cites] J Registry Manag. 2009 Spring;36(1):12-5 [19670693.001]
  • [Cites] Cancer. 2009 Oct 1;115(19):4595-605 [19626648.001]
  • [Cites] Am J Public Health. 2010 May;100(5):861-9 [20299648.001]
  • [Cites] Health Serv Res. 2010 Feb;45(1):172-94 [19878346.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jun;121(3):743-51 [19949856.001]
  • [Cites] Am J Public Health. 2001 Jan;91(1):122-5 [11189803.001]
  • (PMID = 20672356.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA093329; United States / NCI NIH HHS / CA / U01 CA093339; United States / NCI NIH HHS / CA / U01 CA093348; United States / NCI NIH HHS / CA / U01 CA093324; United States / NCI NIH HHS / CA / U01 CA093324-01; United States / NCI NIH HHS / CA / U01 CA093344; United States / NCI NIH HHS / CA / CA093324-01; United States / NCI NIH HHS / CA / U01 CA093326; United States / NCI NIH HHS / CA / U01 CA093332
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS219754; NLM/ PMC2974942
  •  go-up   go-down


7. Guimarães AP, Matos D, Segreto R, Forones NM: [Squamous cell carcinoma of the canal anal]. Arq Gastroenterol; 2001 Jan-Mar;38(1):9-13
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the canal anal].
  • [Transliterated title] Carcinoma espinocelular de canal anal: análise de 11 casos.
  • BACKGROUND: Anal cancer is an uncommon malignancy accounting for only a small (4%) percentage of intestinal cancer.
  • The authors described the clinical aspects and the treatment of the patients with squamous cell carcinoma of the canal anal.
  • PATIENTS: Eleven patients with squamous cell carcinoma treated among 1995 and 1999, were analyzed retrospectively.
  • RESULTS: The most common symptoms were rectal bleeding, local tumor and pain.
  • All were submitted to systemic chemotherapy with 5-fluorouracil and mitomycin and radiotherapy with 4500 cGy.
  • The chemo radiation can be a curable treatment in patients with local disease; conversely in patients with residual disease, abdominoperineal resection must be done.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sex Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11582966.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


8. Kuratate S, Inoue S, Chikakiyo M, Kaneda Y, Harino Y, Hirose T, Yagi T, Saitoh S, Sumitomo M, Fujino R, Satake N: Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case. J Med Invest; 2010 Aug;57(3-4):338-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case.
  • A 74-years old man was referred to our hospital for treatment of a rectal mass.
  • Colonoscopy revealed villous tumor covering all the lower rectal lumen.
  • Rectosigmoidectomy with lymph node dissection was performed with the diagnosis of rectal cancer that metastasized to the liver.
  • Histological and immuno- histochemical features showed coexistent poorly-differentiated small cell neuroendocrine cell (NEC) carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma.
  • However the chemotherapy with FOLFOX and Bevacizumab was performed postoperatively, the patient died in cancer 3 months after surgery.
  • Rectal poorly-differentiated NEC carcinomas are thought to be a tumor with a high malignant potential.
  • Recently, the UICC TNM classifications of malignant tumors, 7th edition and the Guidelines for colorectal NEC tumors of European Neuroendocrine Tumor Society have been published.
  • They would be evaluated, and effective multimodal therapy for NEC carcinomas should be established.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiography. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847536.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Balta Z, Sauerbruch T, Hirner A, Büttner R, Fischer HP: [Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small-cell hepatic carcinoma: case reports and review of the literature]. Pathologe; 2008 Feb;29(1):53-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small-cell hepatic carcinoma: case reports and review of the literature].
  • Primary hepatic neuroendocrine tumors are rare neoplasms.
  • While primary hepatic carcinoid tumors (PHCT) are well-differentiated tumors, primary hepatic small-cell carcinomas (PHSCC) represent the poorly differentiated end of the spectrum of neuroendocrine carcinomas.
  • Within this time, the tumor relapsed 4 times with unchanged histology and immunohistochemistry features.
  • The second patient suffered from small-cell carcinoma of the liver.
  • There were no risk factors for a hepatocellular carcinoma.
  • A neuroendocrine PHSCC was diagnosed.
  • After neoadjuvant cytostatic treatment the carcinoma was completely extirpated and 18 months after treatment the patient is healthy.PHCT and PHSCC have to be clearly separated from hepatocellular and cholangiocellular carcinomas.
  • Surgical resection is the treatment of choice.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carboplatin / administration & dosage. Cell Differentiation. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Rectal Neoplasms / pathology. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Med. 1993 May-Jun;11(3):102-6 [8372237.001]
  • [Cites] Br J Surg. 1989 Mar;76(3):248-9 [2655808.001]
  • [Cites] Dig Dis Sci. 2003 Aug;48(8):1665-7 [12924666.001]
  • [Cites] Clin Nucl Med. 2005 Jul;30(7):530-1 [15965342.001]
  • [Cites] Dtsch Med Wochenschr. 1989 Apr 21;114(16):623-7 [2707129.001]
  • [Cites] Radiat Med. 1995 Jul-Aug;13(4):183-5 [8539446.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2547-50 [10522038.001]
  • [Cites] Surgery. 1992 Dec;112(6):1039-46; discussion 1046-7 [1455307.001]
  • [Cites] J Chin Med Assoc. 2003 Apr;66(4):247-51 [12854878.001]
  • [Cites] Ultrastruct Pathol. 1986;10(4):331-6 [3739044.001]
  • [Cites] Jpn J Clin Oncol. 1999 May;29(5):252-5 [10379337.001]
  • [Cites] Abdom Imaging. 2002 May-Jun;27(3):325-8 [12173364.001]
  • [Cites] Ultrastruct Pathol. 1992 Nov-Dec;16(6):667-72 [1448886.001]
  • [Cites] Med Sci Monit. 2001 Jul-Aug;7(4):746-50 [11433205.001]
  • [Cites] Hepatol Res. 2002 Apr;22(4):313-321 [11929717.001]
  • [Cites] J Comput Assist Tomogr. 1992 Jan-Feb;16(1):99-102 [1729316.001]
  • [Cites] Digestion. 1999 Mar-Apr;60(2):110-6 [10095151.001]
  • [Cites] Abdom Imaging. 2005 May-Jun;30(3):281-5 [15785908.001]
  • [Cites] Am J Clin Pathol. 1988 Apr;89(4):561-4 [3354510.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):210-9 [14745329.001]
  • [Cites] J Comput Tomogr. 1986 Oct;10 (4):313-7 [3780258.001]
  • [Cites] Surgery. 1998 Dec;124(6):1145-52 [9854596.001]
  • [Cites] Pathol Int. 2001 Nov;51(11):874-8 [11844054.001]
  • [Cites] Virchows Arch. 2006 May;448(5):655-8 [16541281.001]
  • [Cites] J Gastroenterol. 1999 Feb;34(1):123-7 [10204622.001]
  • [Cites] Korean J Hepatol. 2005 Sep;11(3):289-92 [16177556.001]
  • [Cites] Radiat Med. 1998 Sep-Oct;16(5):371-3 [9862161.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1119-24 [12201876.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2660-5 [8453589.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1218-20 [16001665.001]
  • [Cites] Surg Today. 2003;33(3):214-8 [12658390.001]
  • [Cites] Am J Surg Pathol. 1992 Aug;16(8):802-7 [1497121.001]
  • [Cites] Histopathology. 1996 Nov;29(5):449-53 [8951490.001]
  • [Cites] Med Princ Pract. 2005 Jul-Aug;14 (4):288-91 [15961944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8078-83 [12048252.001]
  • [Cites] Pathol Int. 1998 Jun;48(6):481-5 [9702863.001]
  • [Cites] J Korean Med Sci. 1998 Jun;13(3):317-20 [9681813.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1171-5 [14654473.001]
  • [Cites] Pathol Oncol Res. 1999;5(1):67-9 [10079384.001]
  • [Cites] Surgery. 1988 Dec;104(6):1080-9 [3194834.001]
  • [Cites] Int J Gastrointest Cancer. 2005;35(2):147-51 [15879630.001]
  • [Cites] Acta Chir Belg. 1999 Dec;99(6):299-302 [10674133.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):218-21 [8667631.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1211-8 [2302669.001]
  • [Cites] Am J Clin Pathol. 1991 Feb;95(2):172-5 [1704179.001]
  • [Cites] J Clin Gastroenterol. 1996 Jul;23(1):60-2 [8835904.001]
  • [Cites] J Clin Ultrasound. 2005 Jul-Aug;33(6):302-4 [16134160.001]
  • [Cites] Am J Gastroenterol. 1993 Jun;88(6):958-61 [8389095.001]
  • [Cites] Br J Radiol. 1999 Feb;72(854):207-9 [10365076.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1146-51 [7194135.001]
  • [Cites] Intern Med. 2005 Sep;44(9):958-62 [16258211.001]
  • [Cites] Acta Pathol Jpn. 1993 Dec;43(12):783-9 [8109257.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2227-30 [11344231.001]
  • [Cites] Jpn J Clin Oncol. 1992 Feb;22(1):54-9 [1374135.001]
  • [Cites] Pathol Int. 1999 Apr;49(4):318-24 [10365851.001]
  • [Cites] Hepatogastroenterology. 2000 Mar-Apr;47(32):528-30 [10791229.001]
  • (PMID = 18210116.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Okonkwo A, Musunuri S, Talamonti M, Benson A 3rd, Small W Jr, Stryker SJ, Rao MS: Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep; 2001 May-Jun;8(3):497-500
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers and prediction of response to chemoradiation in rectal cancer.
  • Preoperative chemotherapy and radiation (chemoradiation) are increasingly used in the treatment of advanced rectal carcinoma to downstage the tumor so that a sphincter sparing procedure is used.
  • This treatment modality has also resulted in not only local disease control but also decreased metastasis and increased survival.
  • Identification of tumor markers that can predict responsiveness to chemoradiation is extremely useful to avoid unnecessary preoperative treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Thymidylate Synthase / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Apoptosis / drug effects. Apoptosis / radiation effects. Biopsy. Cell Division / drug effects. Cell Division / radiation effects. Female. Fluorouracil / therapeutic use. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11295069.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Berghmans T, Crokaert F, Sculier JP: Vibrio cholerae bacteremia in a neutropenic patient with non-small-cell lung carcinoma. Eur J Clin Microbiol Infect Dis; 2002 Sep;21(9):676-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vibrio cholerae bacteremia in a neutropenic patient with non-small-cell lung carcinoma.
  • Vibrio cholerae was isolated from the blood cultures of a neutropenic patient treated with chemotherapy for non-small-cell lung cancer.
  • Attempts to isolate Vibrio spp. from a rectal swab and stool were unsuccessful.
  • Piperacillin/tazobactam treatment resulted in eradication of the microorganism from the patient's blood.
  • [MeSH-major] Bacteremia / diagnosis. Carcinoma, Non-Small-Cell Lung / immunology. Cholera / diagnosis. Immunocompromised Host. Lung Neoplasms / immunology. Neutropenia / immunology. Vibrio cholerae / isolation & purification

  • MedlinePlus Health Information. consumer health - Cholera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12373501.001).
  • [ISSN] 0934-9723
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 16
  •  go-up   go-down


12. Kim JH, Kim HJ, Hong S, Wu HG, Ha SW: Post-hysterectomy radiotherapy in FIGO stage IB-IIB uterine cervical carcinoma. Gynecol Oncol; 2005 Feb;96(2):407-14
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-hysterectomy radiotherapy in FIGO stage IB-IIB uterine cervical carcinoma.
  • OBJECTIVE: This study is a retrospective analysis of stage IB-IIB cervical carcinoma patients who had received postoperative radiotherapy (PORT).
  • The incidences of late rectal, urinary, and small bowel complications of grade 3 or higher were 1.6%, 1.4%, and 1.0%, respectively.
  • Distant metastasis was the major pattern of treatment failure after PORT.
  • Effective systemic chemotherapy might be a breakthrough in improving the outcome of PORT in patients with cervical carcinomas.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661229.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Rabbitt P, Pathma-Nathan N, Collinson T, Hewett P, Rieger N: Sentinel lymph node biopsy for squamous cell carcinoma of the anal canal. ANZ J Surg; 2002 Sep;72(9):651-4
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy for squamous cell carcinoma of the anal canal.
  • BACKGROUND: The current Trans-Tasman Radiation Oncology Group (TROG) protocol for T1 and T2 anal cancers is combination chemotherapy and radiotherapy excluding the inguinal region from the field.
  • Several centres worldwide irradiate both inguinal regions as there is a small incidence of involvement with early stage tumours.
  • We have developed a method of sampling the sentinel node in the groin using established node mapping techniques.
  • The fourth patient had a sentinel node mapped to a meso-rectal node.
  • CONCLUSIONS: The application of this effective technique will allow accurate staging of anal cancers to better plan future treatment regimes.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Sentinel Lymph Node Biopsy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12269917.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


14. Yamazaki K, Yoshino T, Boku N: [Bevacizumab (Avastin)]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1183-91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the identified angiogenic factors, vascular endothelial growth factor (VEGF) is a crucial regulator of angiogenesis in normal and malignant tissue.
  • Some pivotal phase III trials demonstrated that the addition of bevacizumab to conventional chemotherapy showed a survival benefit with acceptable toxicity.
  • The United States Food and Drug Administration approved the use of bevacizumab for patients with unresectable colorectal cancer and unresectable non-squamous, non small cell lung cancer.
  • The usage of bevacizumab will be stipulated in combination with 5-fluorouracil containing chemotherapy at a dose of 5 mg/kg or 10 mg/kg given every 14 days.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Breast Neoplasms / drug therapy. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Non-Small-Cell Lung / drug therapy. Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Drug Administration Schedule. Drug Approval. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lung Neoplasms / drug therapy. Male. Organoplatinum Compounds / administration & dosage. Vascular Endothelial Growth Factor A / biosynthesis

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687199.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0 / Vascular Endothelial Growth Factor A; 04ZR38536J / oxaliplatin; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol
  • [Number-of-references] 33
  •  go-up   go-down


15. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol; 2001 Jul;53(3):259-65
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Treatment options for patients with recurrent brain metastases are extremely limited.
  • This study was designed to determine the safety and efficacy of temozolomide in the treatment of recurrent or progressive brain metastases.
  • PATIENTS AND METHODS: Forty-one patients (11 men, 30 women) with a median KPS of 80 were treated with temozolomide 150 mg/m2/day (200 mg/m3/day if no prior chemotherapy) for 5 days; treatment cycles were repeated every 28 days.
  • Primary tumor types included 22 non-small cell lung, 10 breast, three melanoma, two small cell lung, two rectal, one ovarian and one endometrial cancer.
  • Both objective responses were seen in patients with non-small cell lung cancer.
  • Therefore, temozolomide may be a reasonable treatment option for some patients with recurrent brain metastases.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / therapeutic use
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Disease Progression. Female. Humans. Lung Neoplasms. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):229-38 [1374064.001]
  • [Cites] Am J Clin Oncol. 1997 Apr;20(2):158-60 [9124191.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):249-54 [11300333.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):765-73 [8625178.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):517-26 [8823779.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1063-70 [9060546.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):600-4 [7674007.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 4;87(1):34-40 [7666461.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1599-605 [10193952.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):527-36 [8823780.001]
  • [Cites] Br J Neurosurg. 1994;8(6):717-23 [7718169.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10 ):1769-74 [9815562.001]
  • (PMID = 11718258.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


16. Heinemann V, Moosmann N: [Neoadjuvant and adjuvant therapies for solid tumours]. MMW Fortschr Med; 2007 Sep 6;149(35-36):27-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant and adjuvant therapies for solid tumours].
  • Today adjuvant or neoadjuvant therapies are standard treatment for many types of cancer.
  • Chemotherapy, radiotherapy, hormone therapy or immunotherapy applied before, during or after an operation can lower the risk of relapse and hence, increase the chances of a cure.
  • After neoadjuvant therapy, frequently the organ does not have to be removed in the subsequent operation.
  • Depending on the risk of relapse, adjuvant therapies are employed after due consideration of benefit, risk and duration of treatment.
  • [MeSH-major] Chemotherapy, Adjuvant. Neoadjuvant Therapy. Neoplasms / therapy. Radiotherapy, Adjuvant
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / surgery. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophageal Neoplasms / surgery. Female. Humans. Informed Consent. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Lung Neoplasms / surgery. Male. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery. Prognosis. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Risk Factors. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944281.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


17. Kouvaris JR, Miliadou A, Kouloulias VE, Kolokouris D, Balafouta MJ, Papacharalampous XN, Vlahos LJ: Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie; 2007 Jul;30(7):361-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to evaluate the effectiveness and possible toxicity of the combination of temozolomide (TMZ) with whole-brain irradiation (WBI) in the treatment of brain metastases from solid tumors.
  • PATIENTS AND METHODS: 33 patients with brain metastases were included in the study and treated with TMZ 60 mg/m2/day (days 1-16) concomitantly with WBI (36 Gy/12 fractions given in 16 days).
  • One month after the end of radiotherapy, 6 cycles of TMZ were administered as adjuvant treatment (200 mg/m2/day for 5 consecutive days every 28 days).
  • RESULTS: Responses were assessed using computed tomography at the end of the 3rd and 6th cycle of chemotherapy.
  • In patients with metastases from lung cancer the objective response rate was 11/14 (78.6%) after both the 3rd and the 6th cycle of treatment.
  • The high incidence of hepatotoxicity (45.5%) might be related to concomitantly administered antiepileptic drugs and not to TMZ.
  • CONCLUSION: WBI combined with TMZ as concomitant and adjuvant treatment is effective in treating brain metastases, with acceptable mild side effects.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / secondary. Cranial Irradiation. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Breast Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / secondary. Chemotherapy, Adjuvant. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy. Male. Melanoma / drug therapy. Melanoma / mortality. Melanoma / radiotherapy. Melanoma / secondary. Middle Aged. Mouth Neoplasms / drug therapy. Mouth Neoplasms / mortality. Mouth Neoplasms / radiotherapy. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / mortality. Neoplasms, Unknown Primary / radiotherapy. Palliative Care. Rectal Neoplasms / drug therapy. Rectal Neoplasms / mortality. Rectal Neoplasms / radiotherapy. Research Design. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2007 Jul;30(7):350-1 [17596741.001]
  • (PMID = 17596744.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


18. Kemmner W, Wan K, Rüttinger S, Ebert B, Macdonald R, Klamm U, Moesta KT: Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer. FASEB J; 2008 Feb;22(2):500-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemes and heme proteins are vital components of essentially every cell of virtually every eukaryote organism.
  • Previously, we demonstrated accumulation of the heme precursor protoporphyrin-IX (PpIX) in gastrointestinal tumor tissues.
  • Here, we describe a significant down-regulation of ferrochelatase (FECH) mRNA expression in gastric, colonic, and rectal carcinomas.
  • Accordingly, in an in vitro model of several carcinoma cell lines, ferrochelatase down-regulation and loss of enzymatic activity corresponded with an enhanced PpIX-dependent fluorescence.
  • Direct detection of PpIX in minute amounts was achieved by a specifically developed pulsed solid-state laser dual delay fluorimetry setup.
  • Silencing of FECH using small interfering RNA (siRNA) technology led to a maximum 50-fold increased PpIX accumulation, imageable by a specifically adapted two-photon microscopy unit.
  • Our results show that in malignant tissue a transcriptional down-regulation of FECH occurs, which causes endogenous PpIX accumulation.
  • Furthermore, accumulation of intracellular PpIX because of FECH siRNA silencing provides a small-molecule-based approach to molecular imaging and molecular therapy.
  • [MeSH-major] Colonic Neoplasms / enzymology. Ferrochelatase / metabolism. Protoporphyrins / metabolism. RNA, Small Interfering / genetics
  • [MeSH-minor] Aminolevulinic Acid / pharmacology. Cell Line, Tumor. Gene Expression Regulation, Enzymologic / drug effects. Heme / metabolism. Heme Oxygenase (Decyclizing) / metabolism. Humans. RNA, Messenger / genetics. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875605.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protoporphyrins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 42VZT0U6YR / Heme; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid; EC 1.14.99.3 / Heme Oxygenase (Decyclizing); EC 4.99.1.1 / Ferrochelatase
  •  go-up   go-down


19. Ryan P, Nguyen VH, Gholoum S, Carpineta L, Abish S, Ahmed NN, Laberge JM, Riddell RH: Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol; 2009 Mar;33(3):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy.
  • We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma.
  • Immunohistochemistry can rule out many of these morphologically similar tumors but differentiation from clear cell sarcoma may require reverse transcription-polymerase chain reaction.
  • We discuss the determination of pathologic features indicative of malignancy in PEComa, which is complicated in the gastrointestinal tract due to the small number of cases, variability of pathologic features reported, and inconsistent reporting of outcome.
  • We propose that a minimum dataset for gastrointestinal PEComa should include these features along with mitotic count, infiltrative border, and tumor stage analogous to that used in colorectal carcinoma.
  • [MeSH-major] Perivascular Epithelioid Cell Neoplasms / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092636.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Fesneau M, Champeaux-Orange E, Hennequin C: [Anal cancer]. Cancer Radiother; 2010 Nov;14 Suppl 1:S120-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anal canal epidermoid carcinomas represent 1.2% of digestive cancers and 6% of ano-rectal cancers.
  • For localized diseases, the treatment is based on radiotherapy with or without chemotherapy (5-FU and cisplatin or mitomycin), according to tumour and nodal extension.
  • The recommended treatment dose is 45 Gy in the anal canal, the mesorectum, pararectal lymph nodes, and inguinal lymph nodes.
  • An additional dose of 15 to 20 Gy is delivered in the initial tumour for good responders.
  • The organs at risk to be considered are bladder, femur heads, small intestine and vulva.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Dosage
  • [MeSH-minor] Combined Modality Therapy. France. Humans. Incidence. Prognosis

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21129654.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Kube R, Meyer F, Bien N, Schmidt C, Mroczkowski P, Dalicho S, Lippert H: [Surgical management of bevacizumab-associated peritonitis due to perforation]. Zentralbl Chir; 2009 Sep;134(5):462-7
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Chirurgisches Management der perforationsbedingten Peritonitis im Zusammenhang mit einer Bevacizumab-Therapie.
  • Roche, Genentech) is the first anti-angiogenic agent to be approved for the routine clinical treatment of cancer.
  • It was the aim of this study, based on exemplary cases of the reporting clinic as well as on published experiences, to characterise the specific clinical findings, the extraordinary pathogenesis, and the therapeutic outcome of such cases of peritonitis caused by perforation after antibody treatment.
  • METHODS: Data of all patients with perforation-caused peritonitis due to bevacizumab therapy since its clinical inauguration were sought in i) the database of the reporting clinic (case series), ii) in the published literature for comparison (historical comparative group) and iii) analysed with regard to results of the surgical management (evaluated parameters: rate of anastomotic insufficiency / disturbances of wound healing, morbidity, mortality).
  • RESULTS: Over a time period of 4 years (from 2 / 1 / 2004 to 1 / 31 / 2008), overall 15 patients were found in this study, among whom 4 patients came from the reporting clinic (mean age, 57 years; males : females = 2 : 2).
  • The mean duration of antibody (Ab) treatment until occurrence of the complication was 70 days (range: 8-150 days).
  • All patients with an anastomosis developed an anastomotic insufficiency (100 %).
  • CONCLUSIONS: Peritonitis after GI perforation due to bevacizumab-based Ab treatment needs to be considered as a rare but serious and life-threatening complication.
  • Impairment of wound healing because of the inhibition of angiogenesis is the reason for a different management of GI perforation under these conditions compared with the standard surgical treatment of peritonitis of other causes.
  • [MeSH-major] Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Intestinal Perforation / chemically induced. Intestinal Perforation / surgery. Neoplasms / drug therapy. Peritonitis / chemically induced. Peritonitis / surgery
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Breast Neoplasms / drug therapy. Carcinoma, Bronchogenic / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Case-Control Studies. Female. Hospital Mortality. Humans. Ileostomy. Lung Neoplasms / drug therapy. Male. Middle Aged. Ovarian Neoplasms / drug therapy. Postoperative Complications / chemically induced. Postoperative Complications / mortality. Postoperative Complications / surgery. Rectal Neoplasms / drug therapy. Surgical Wound Dehiscence / chemically induced. Surgical Wound Dehiscence / mortality. Surgical Wound Dehiscence / surgery. Survival Rate. Wound Healing / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag Stuttgart-New York.
  • (PMID = 19757347.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


22. Gounant V, Milleron B, Assouad J, Gligorov J, Lavole A, Wislez M, Brian E, Bazelly B, Grunenwald D: [Bevacizumab and invasive procedures: practical recommendations]. Rev Mal Respir; 2009 Feb;26(2):221-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As first line chemotherapy Bevacizumab, associated with a platinum based regime, improves survival in patients with metastatic, non small cell, non epidermoid bronchial carcinoma.
  • This treatment produces specific secondary effects related to its anti-angiogenic action.
  • We depend, therefore, principally on studies of neo-adjuvant chemotherapy in metastatic colo-rectal cancer prior to excision of hepatic metastases and on our own experience of excision of pulmonary metastases from solid tumours treated with bevacizumab.
  • We recommend a delay of 2 days between implantation of an intravenous device and the initiation of bevacizumab, a delay of at least 5 weeks between the last injection of bevacizumab and invasive surgery and a delay of 4 weeks between surgery and the initiation of bevacizumab treatment.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Bronchoscopy. Catheterization, Central Venous. Cicatrix / prevention & control. Fluoroscopy. Humans. Neoplasms / surgery. Skin Ulcer / prevention & control. Time Factors. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319116.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


23. Urbánek L, Krcmová L, Solichová D, Melichar B, Opletalová V, Solich P: Development and validation of a liquid chromatography method for the simultaneous determination of alpha-tocopherol, retinol and retinyl esters in human serum using a monolithic column for the monitoring of anticancer therapy side effects. J Sep Sci; 2006 Nov;29(16):2485-93
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and validation of a liquid chromatography method for the simultaneous determination of alpha-tocopherol, retinol and retinyl esters in human serum using a monolithic column for the monitoring of anticancer therapy side effects.
  • Therefore, a simple and rapid reversed-phase high-performance liquid chromatography procedure for selective and sensitive determination of retinol, a-tocopherol, and retinyl esters (retinyl-palmitate and retinyl-stearate) in blood serum has been developed and presented in this study.
  • The total time of analysis was 6 min.
  • Detection of retinol, alpha-tocopherol, and retinyl esters was carried out at 325, 295, and 330 nm, respectively.
  • For practical assessment of the method, the vitamin A absorption test was performed on seven healthy controls as well as on six patients with non-small cell lung carcinoma or head and neck carcinoma previously treated by chemotherapy and/or radiotherapy, six patients with rectal carcinoma before chemoradiotherapy, four patients with gastrointestinal stromal tumor (GIST) before treatment with imatinib, and a breast cancer patient with chemotherapy-induced diarrhea.
  • Present data demonstrate the feasibility of large scale HPLC determination of vitamin E, vitamin A, and retinyl esters in human serum using a silica monolithic column, and this method may represent a valuable aid in the laboratory monitoring of the toxicity of anticancer therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Chromatography, High Pressure Liquid / methods. Drug Monitoring / methods. Esters / analysis. Vitamin A / analysis. alpha-Tocopherol / analysis
  • [MeSH-minor] Absorption. Benzamides. Calibration. Chromatography / methods. Diarrhea / chemically induced. Gastrointestinal Stromal Tumors / drug therapy. Humans. Imatinib Mesylate. Piperazines / adverse effects. Piperazines / pharmacology. Pyrimidines / adverse effects. Pyrimidines / pharmacology. Reproducibility of Results. Time Factors

  • MedlinePlus Health Information. consumer health - Vitamin A.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17154129.001).
  • [ISSN] 1615-9306
  • [Journal-full-title] Journal of separation science
  • [ISO-abbreviation] J Sep Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Esters; 0 / Piperazines; 0 / Pyrimidines; 11103-57-4 / Vitamin A; 8A1O1M485B / Imatinib Mesylate; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


24. Chen SW, Liang JA, Yang SN, Lin FJ: High dose-rate brachytherapy for elderly patients with uterine cervical cancer. Jpn J Clin Oncol; 2003 May;33(5):221-8
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The need for radiotherapy (RT) in cancer treatment for the elderly patient is growing.
  • The purpose of this study was to analyze the efficacy and complication rate for radiotherapy, using external-beam irradiation (EBRT) and high dose-rate intracavitary brachytherapy (HDRICB), for patients aged 70 years or older with carcinoma of the uterine cervix.
  • A retrospective analysis was conducted to compare the outcome of radiation therapy for the 179 patients under 70 years of age (younger group) and the 79 patients aged 70 years or older (older group).
  • After a total EBRT dose of 40-45 Gy/20 in 25 fractions, irradiating the whole pelvis over 4-5 weeks, dosage for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease was boosted to 54-58 Gy, with central shielding.
  • Total prescribed Point A dosages (EBRT + HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while for larger lesions (stage IIB-IVA) analogous dosages were 59-75.6 Gy (median, 65.6 Gy).
  • Twelve (15.0%) of the 79 older patients and 14 (7.8%) of the 179 younger patients developed RTOG grade 3-4 rectal complications (P = 0.12), while seven (8.9%) of the 79 older patients and 10 (5.6%) of the 179 younger patients developed RTOG grade 3-4 small bowel complications (P = 0.34).
  • CONCLUSION: Radiation therapy, consisting of a combination of EBRT and three or four fractions of HDRICB, proved to be effective for older patients.
  • Further optimization of treatment policy is essential by changing the HDRICB fractionation strategy, shortening the treatment time and designing combination drug regimens that are both effective and tolerable during radiotherapy.
  • [MeSH-major] Brachytherapy. Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adult. Age Factors. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / radiotherapy. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Radiation Injuries / epidemiology. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12865465.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Hemal AK, Kumar R, Seth A, Gupta NP: Complications of laparoscopic radical cystectomy during the initial experience. Int J Urol; 2004 Jul;11(7):483-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While open radical cystectomy is now a standard procedure, laparoscopic radical cystectomy is still in its infancy.
  • We performed this surgery laparoscopically in 11 patients and review the procedure specific complications.
  • These included injury to the external iliac vein in one patient and a small rectal tear in two.
  • One patient had margins positive and received cisplatinum-based chemotherapy.
  • Absence of local recurrence or metastatic disease at four years of follow up suggests that the procedure is oncologically valid.
  • Laparoscopic radical cystectomy is a new procedure and it is important to critically analyze the complications in order to reduce their occurrence and allow the development of a better technique.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / adverse effects. Cystectomy / methods. Laparoscopy / adverse effects. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15242356.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


26. Durdux C: [Cisplatin and derivatives with radiation therapy: for what clinical use?]. Cancer Radiother; 2004 Nov;8 Suppl 1:S88-94
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cisplatin and derivatives with radiation therapy: for what clinical use?].
  • The first part of this overview will describe biological mechanisms of interaction between radiation therapy and platinum derivatives.
  • [MeSH-major] Carboplatin / therapeutic use. Cisplatin / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy. Organoplatinum Compounds / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Anus Neoplasms / drug therapy. Anus Neoplasms / mortality. Anus Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / radiotherapy. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Female. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Leukemia P388 / drug therapy. Leukemia P388 / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy. Male. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / radiotherapy. Meta-Analysis as Topic. Mice. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Rats. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Time Factors. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679253.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Radiation-Sensitizing Agents; 04ZR38536J / oxaliplatin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 71
  •  go-up   go-down


27. Yegüez JF, Martinez SA, Sands DR, Sands LR, Hellinger MD: Colorectal malignancies in HIV-positive patients. Am Surg; 2003 Nov;69(11):981-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the development of more effective medications, those infected with HIV are living longer.
  • Twelve patients (9 males and 3 females), mean age 41 years, were identified with the following neoplasm: 6 adenocarcinomas (ACA), 5 non-Hodgkin lymphomas (NHL), and 1 small-cell carcinoma.
  • Intravenous drug abuse was the main risk factor for HIV.
  • Five out of six patients with ACA had metastatic disease at the time of diagnosis.
  • One patient with stage II ACA developed early liver metastases after colonic resection.
  • These patients developed tumors at earlier ages and were diagnosed at an advanced stage.
  • The use of the new antiretroviral therapy regimens should be further evaluated to know its impact in the survival.


28. Sela B: [Survivin: anti-apoptosis protein and a prognostic marker for tumor progression and recurrence]. Harefuah; 2002 Jan;141(1):103-7, 123
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recently discovered 16.5 kDa protein survivin was found to inhibit the two early apoptotic enzymes caspase-3 and caspase-7, thus preventing programmed cell death.
  • Numerous reports have demonstrated the expression of survivin in various tumors such as neuroblastoma, melanoma, bladder carcinoma, breast and lung non-small cell tumors, esophegeal and colo-rectal carcinomas and leukemic cells.
  • In contrast, this protein was not traced in adjacent normal tissues by either immunohistochemical staining or by PCR analysis of the expression of survivin mRNA.
  • Importantly, there seems to be a positive correlation between survivin expression and tumor grading, as well as an indication of tumor recurrence after resection or chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11851094.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / Cysteine Proteinase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 27
  •  go-up   go-down


29. O'Connell JB, Maggard MA, Ko CY: Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol; 2004 Nov;11(11):962-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous studies report underuse of radiation and chemotherapy in the elderly, yet few have examined the rates of use (or underuse) of surgery.
  • METHODS: By using the Surveillance, Epidemiology, and End RESULTS database (1988-1997), patients (> or =40 years) were identified with localized adenocarcinoma of the breast, esophagus, stomach, pancreas, colon, or rectum; non-small-cell lung carcinoma; and sarcoma (n = 200,360).
  • However, CDS rates were >90% for breast and colon and >84% for rectal cancer in all age groups.

  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2004 Nov;11(11):951-2 [15525821.001]
  • (PMID = 15525824.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Shia J, Teruya-Feldstein J, Pan D, Hegde A, Klimstra DS, Chaganti RS, Qin J, Portlock CS, Filippa DA: Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am J Surg Pathol; 2002 Feb;26(2):216-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of cases (22 of 26, 84.6%) involved small bowel, four involved colorectum alone, and two involved the ileocecal valve.
  • Within the small bowel the duodenum was the most commonly involved site (10 cases).
  • Initial treatment modalities included surgery plus chemotherapy (nine cases), surgery alone (seven cases), chemotherapy alone (four cases), observation alone (four cases), and chemotherapy and abdominal radiation (one case).
  • One case presented with rectal polyps and was treated with polypectomy.
  • A complete response was observed in 15 of 22 cases that received treatment, and of the 15 cases, five recurred 27-60 months after the initial diagnosis.
  • Recurrence and progression were associated with histologic transformation to diffuse large cell lymphoma in one case.
  • No significant correlation was identified between treatment response and various clinical and pathologic features.
  • One patient died of a concomitant pancreatic carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Cytogenetics. Digestive System Surgical Procedures. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11812943.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


31. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG: Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs; 2007 Apr;25(2):131-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-one patients with the following malignancies were treated: colon carcinoma 4, non-small cell lung carcinoma 4; anaplastic astrocytoma 3, glioblastoma multiforme 3, bladder carcinoma 2, sarcoma 2, and ovarian carcinoma, rectal hemangiopericytoma, and pancreatic carcinoma 1 each.
  • The therapy was well tolerated overall.
  • Study designs with more convenient treatment schedules and specific molecular correlates may help to further delineate the mechanism of action of this compound.
  • Future studies evaluating PBA's ability to induce histone acetylation and cell differentiation alone or in combination with other anti-neoplastics are recommended.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Phenylbutyrates / therapeutic use
  • [MeSH-minor] Adult. Aged. Biotransformation. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 15;80(10):2604-9 [1421378.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):379-87 [9816181.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):672-81 [7674018.001]
  • [Cites] Angiology. 1956 Apr;7(2):156-8 [13314153.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2203-9 [7691251.001]
  • [Cites] Adv Exp Med Biol. 1997;400A:501-5 [9547596.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3047-55 [11595694.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1099-103 [9615772.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7304-9 [3191501.001]
  • [Cites] J Clin Pharmacol. 1995 Apr;35(4):368-73 [7650225.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):577-81 [11107121.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):889-93 [9499451.001]
  • [Cites] Br J Haematol. 1991 Oct;79 Suppl 1:81-3 [1931716.001]
  • [Cites] Ther Drug Monit. 1996 Dec;18(6):714-20 [8946671.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1690-4 [8137283.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 May;47(5):385-90 [11391852.001]
  • [Cites] Leukemia. 2006 Feb;20(2):212-7 [16357841.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3906-11 [15851763.001]
  • [Cites] Stat Med. 1991 Nov;10(11):1647-64 [1792460.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1988-92 [1372534.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] N Engl J Med. 1984 Jun 21;310(25):1630-4 [6427608.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):865-72 [9816242.001]
  • [Cites] Blood. 1989 Apr;73(5):1298-306 [2467706.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3998-4002 [11358817.001]
  • [Cites] Pediatr Res. 1991 Feb;29(2):147-50 [2014149.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):507-14 [7829265.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1509-16 [10389940.001]
  • [Cites] Jpn J Ophthalmol. 2000 Nov-Dec;44(6):601-9 [11094173.001]
  • [Cites] J Cell Biochem. 2004 Nov 1;93(4):819-29 [15389886.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 1):E801-7 [9612237.001]
  • [Cites] Blood. 1992 Sep 15;80(6):1576-81 [1381630.001]
  • [Cites] Cell Growth Differ. 1996 Dec;7(12):1609-15 [8959328.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2292-300 [11489804.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2932-8 [7773944.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2923-7 [8187079.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2765-71 [15517883.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1243-53 [10450753.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • (PMID = 17053987.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01: CA69856
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phenylbutyrates
  •  go-up   go-down


32. Yi SK, Yoder M, Zaner K, Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician; 2007 Mar;10(2):285-90
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy of symptomatic recurrent bladder cancer.
  • BACKGROUND: Palliative radiation therapy (RT) is an established tool in the management of symptoms caused by malignancies.
  • Most data on palliative RT is in regard to its use in the treatment of painful bone metastases.
  • There are also data that support RT palliation for locally advanced or recurrent rectal, prostate, and gynecological cancers.
  • CASE REPORT: An 80-year-old woman with recurrent bladder cancer and intractable pelvic pain refractory to oral and transdermal pain medications, received palliative pelvic RT to a dose of 50 Gy (5000 cGy) in 25 fractions with complete resolution of pain.
  • The patient was originally found to have dysuria, frequency, and hematuria, secondary to an invasive high grade transitional cell carcinoma of the bladder with an adenocarcinoma component, AJCC pT2b N1 M0 Stage IV, for which she underwent a radical cystectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial vaginectomy, and ileal conduit reconstruction.
  • After undergoing 4 cycles of adjuvant chemotherapy, the patient did well for 5 months with no evidence of symptomatic, clinical, or radiographic recurrence of disease.
  • The patient was treated with another course of chemotherapy and pain was managed with relatively low doses of opioid medication (25mcg transdermal fentanyl patch, and oxycodone 5mg bid).
  • Ultimately a pain medication regimen of 200mcg transdermal fentanyl patch q2 days, oxycontin 20mg bid, oxycodone 5 - 10mg q 4 hours, ibuprofen 400mg q 8 hours, and gabapentin 600mg TID was not effective in controlling pain.
  • She received a total of 5000cGy over 25 fractions to a small pelvis field over 5 weeks and reported complete pain resolution.
  • She was able to decrease pain medications, increase overall activity, and gain significant improvement in sleep quality and appetite even early on in the course of her radiation therapy.
  • CONCLUSIONS: Palliative radiation therapy has been well studied in the setting of bone metastases and treatment of hematuria for locally advanced bladder cancer.
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Quality of Life. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387350.001).
  • [ISSN] 1533-3159
  • [Journal-full-title] Pain physician
  • [ISO-abbreviation] Pain Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Iyer R, Egloff L, Fraas J, Harris JD: Urinary and rectal incontinence during gabapentin therapy. J Support Oncol; 2008 Apr;6(4):152
Hazardous Substances Data Bank. GABAPENTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary and rectal incontinence during gabapentin therapy.
  • [MeSH-minor] Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Female. Humans. Lung Neoplasms / drug therapy. Pain / drug therapy

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491681.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Anticonvulsants; 0 / Cyclohexanecarboxylic Acids; 56-12-2 / gamma-Aminobutyric Acid; 6CW7F3G59X / gabapentin
  •  go-up   go-down


34. The FDA approves drugs for colorectal cancer, lung cancer. FDA Consum; 2007 Jan-Feb;41(1):5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The FDA approves drugs for colorectal cancer, lung cancer.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Approval. Humans. United States. United States Food and Drug Administration

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354284.001).
  • [ISSN] 0362-1332
  • [Journal-full-title] FDA consumer
  • [ISO-abbreviation] FDA Consum
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / panitumumab; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


35. Weller M: Radiochemotherapy for brain metastasis: how to define a role for temozolomide. Onkologie; 2007 Jul;30(7):350-1
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / secondary. Cranial Irradiation. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / secondary. Chemotherapy, Adjuvant. Clinical Trials, Phase II as Topic. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Melanoma / drug therapy. Melanoma / radiotherapy. Melanoma / secondary. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / radiotherapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Research Design. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2007 Jul;30(7):361-6 [17596744.001]
  • (PMID = 17596741.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Editorial; Comment
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


36. Natale D, Orlando D: [Chemoradiotherapy. Therapeutic indications: the doctor's point of view]. Suppl Tumori; 2004 Jul-Aug;3(4):S123-4
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoradiotherapy. Therapeutic indications: the doctor's point of view].
  • [MeSH-major] Combined Modality Therapy. Neoplasms / drug therapy. Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Dose Fractionation. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Radiotherapy, Conformal. Randomized Controlled Trials as Topic. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15206236.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement